financetom
Business
financetom
/
Business
/
BRIEF-PicoCELA Files For US IPO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-PicoCELA Files For US IPO
Nov 4, 2024 11:50 AM

Oct 31 (Reuters) -

PicoCELA:

* PICOCELA INC FILES FOR U.S. IPO - SEC FILING

* PICOCELA INC.: INTEND TO APPLY TO LIST THE ADSS ON THE

NASDAQ

UNDER SYMBOL "PCLA."

* PICOCELA INC. SAYS EXPECT US IPO PRICE OF ADSS TO BE IN

THE

RANGE OF $4.00 TO $6.00 PER ADS

* PICOCELA INC SEES U.S. IPO OF UP TO 2.0 MILLION ADSS

* PICOCELA INC.: BENJAMIN SECURITIES & PRIME NUMBER CAPITAL

ARE

THE UNDERWRITERS FOR IPO

Source text:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Pfizer, Baxter, Thermo Fisher, Others FTC Cautioned to Extend Merger Review Period
Market Chatter: Pfizer, Baxter, Thermo Fisher, Others FTC Cautioned to Extend Merger Review Period
Apr 4, 2024
01:51 PM EDT, 04/04/2024 (MT Newswires) -- Pfizer ( PFE ) , Baxter International ( BAX ) , Thermo Fisher Scientific ( TMO ) and around 200 other companies were warned by the US Federal Trade Commission that their merger deals could still be challenged even after the 30-day antitrust review period, Bloomberg reported Thursday. The FTC sent at least...
Goldman, Morgan Stanley must face investors' lawsuit over Archegos collapse
Goldman, Morgan Stanley must face investors' lawsuit over Archegos collapse
Apr 4, 2024
NEW YORK, April 4 (Reuters) - A New York state appeals court said former ViacomCBS investors may sue Goldman Sachs ( GS ) , Morgan Stanley ( MS ) and other banks that underwrote two stock offerings for the media company, upholding a ruling that banks fear could upend capital markets. Thursday's decision by the Appellate Division in Manhattan came...
Top Midday Decliners
Top Midday Decliners
Apr 4, 2024
01:54 PM EDT, 04/04/2024 (MT Newswires) -- eFFECTOR Therapeutics ( EFTR ) Chief Executive Officer Steve Worland said there is no obvious path forward to continue developing tomivosertib in frontline NSCLC based on the data currently available after disclosing topline results for the phase 2 trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer. The stock plummeted 81%...
Hedge funds rally in Q1, powered by gains in equities
Hedge funds rally in Q1, powered by gains in equities
Apr 4, 2024
By Carolina Mandl NEW YORK, April 3 (Reuters) - Hedge funds capped the first quarter with gains across different strategies, as a rally in stocks, some commodities and the dollar helped the industry weather a less shiny period for bonds, investors said. Fundamental equities long/short hedge funds were up 6.28% in the first quarter, while systematic long/short funds posted gains...
Copyright 2023-2026 - www.financetom.com All Rights Reserved